Aabø-Evensen & Co acted at legal advisor to Optinose in connection with a $100 million Debt Financing from Athyrium Capital Management

Aabø-Evensen & Co acted at legal advisor to Optinose in connection with a $100 million Debt Financing from Athyrium Capital Management

Optinose (NASDAQ:OPTN), a pharmaceutical company focused on patients treated by ear, nose and throat (ENT) and allergy specialists has entered into a $100 million debt financing agreement with funds managed by Athyrium Capital Management, LP, a leading global healthcare-focused investment firm.

"This financing increases our financial flexibility as we prepare to launch XHANCE™," stated Chief Executive Officer, Peter Miller. "We are excited to partner with the Athyrium team as we remain focused on bringing XHANCE to market in the second quarter of this year."

At closing of the agreement, $75 million in aggregate principal amount of the Senior Secured Notes were issued. An additional $25 million will be available to Optinose in 2019 subject to the achievement of a sales milestone and certain other conditions. The Senior Secured Notes mature in June 2023.

Aabø-Evensen & Co was one of the legal advisors that assisted Optinose in connection with the transaction.

Click here to be redirected to Nasdaq.com’s press release.